Organon & Co | OGN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Celltrion KRW 46.98B 579.12B 2025-12
Cspc Pharmaceutical CNY 4.01B 329.18M 2025-12
Deva Holding AS TRY 1.32B 235.77M 2023-09
Dianthus Therapeutics USD 284K 112K 2025-12
Divis Laboratories Ltd INR 16.59B 2.05B 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Kangmei Pharma CNY 238.34M 31.95M 2026-03
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Laboratorios Farma EUR 105.28M 177.08M 2025-06
Medical Developments International AUD 7.35M 7.37M 2025-06
Merck USD 10.85B 2.57B 2025-12
Neuren Pharmaceuticals AUD 6.69M 6.37M 2025-06
Novartis USD 10.82B 694M 2025-09
Organigram Holdings CAD 23.32M 8.52M 2025-12
Organon & Co USD 854M 3M 2025-12
Pharma Mar EUR 39.24M 47.46M 2026-03
Qiagen NV USD 325.27M 19.53M 2025-12
Sartorius EUR 414.5M 18.3M 2026-03
Sino Biopharmaceutical CNY 10.5B 2.53B 2024-12
Tilray USD 57.47M 10.16M 2025-06
Zealand Pharma A/S 68.91M 19.35M 2025-12